Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.

NCT04271189 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria di Parma as lead sponsor.

NCT NCT04271189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04271189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2020
Completion date
December 31, 2024
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed type 2 diabetes